• Study on Early Stage Follicular Lymphoma: Evaluating Radiotherapy with Rituximab or Obinutuzumab for Patients with Early Stage Nodal Follicular Lymphoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany
  • Study on Patiromer for Improving RAAS Treatment in Patients with Chronic Kidney Disease Stages 3b/4

    Recruiting

    3 1 1
    Investigated Diseases:
    The Netherlands
  • Study on EXL01 with Nivolumab and FOLFOX for First-Line Treatment in Patients with PD-L1 CPS ≥5 Metastatic Gastric Cancer

    Recruiting

    2 1 1 1
    France
  • Study on the Safety and Effects of Vosilasarm Alone and in Combination for Patients with Relapsed Advanced or Metastatic Breast Cancer

    Recruiting

    1 1 1 1
    Investigated Drugs:
    Spain
  • Study on Apixaban and Edoxaban for Preventing Stroke in Patients with Recent Perioperative Atrial Fibrillation After Noncardiac Surgery

    Recruiting

    3 1 1 1
    Belgium Denmark Finland France Germany Greece +5
  • Study Comparing Standard and Adjusted Doses of Alectinib for Patients with ALK Positive Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France The Netherlands
  • Study on Ponatinib for Treating Recurrent or Refractory Leukemias and Solid Tumors in Children

    Recruiting

    1 1 1 1
    Investigated Drugs:
    Belgium France Italy The Netherlands Spain Sweden
  • Study on Dexamethasone and Sodium Chloride for Treating Severe Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

    Recruiting

    3 1 1
    Investigated Diseases:
    Belgium France Greece Spain
  • Study on C1 Esterase Inhibitor for Treating and Preventing Hereditary Angioedema Attacks in Patients with C1-INH Deficiency

    Recruiting

    3 1 1
    Bulgaria Romania
  • Study Comparing Avatrombopag and Rituximab for Adults with Immune Thrombocytopenia Not Responding to Corticosteroids

    Recruiting

    3 1 1 1
    Investigated Drugs:
    Norway

powered by